Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3779 - The expression of HER2-gene polymorphisms -1985G>T and P1170A C>G and their association with the risk of development of lung adenocarcinoma


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Ivan Aleric


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


I. Aleric1, D. Katalinic1, A. Vcev1, E. Kattner2, S. Bildat2, V. Krieger-Borgstaedt2, L. Toetome3

Author affiliations

  • 1 Department Of Clinical Medicine, Faculty of Dental Medicine and Health, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 - Osijek/HR
  • 2 Department Of Hematology And Medical Oncology, Herford Teaching Hospital, Medical Campus OWL, 32049 - Herford/DE
  • 3 Department Of Molecular Medicine, Center for Cancer Medicine, 0424 - Oslo/NO


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3779


HER2-gene mutations are considered to be an important prognostic factor in patients with lung cancer. The aim of our study was to assess the frequency and significance of HER2-gene single nucleotide polymorphisms -1985G>T and P1170AC>G among the patients with small-cell and non-small cell lung cancer and to compare this data to healthy subjects.


The study was performed among 359 patients (69% males and 31% females; mean age of 59.96 ± 18.24 years) with diagnosis of stage IV small-cell (24.6% of patients) and non-small cell lung cancer (75.4% of patients) compared to 167 healthy subjects (72% males and 28% females; mean age of 69.96 ± 11.74 years). The frequencies of two polymorphisms of the HER-2-gene -1985G>T and P1170A C>G were detected using the quantitative real-time polymerase chain reaction (qRT-PCR) restriction fragment length polymorphism (RFLP) assay. The study was conducted according to the Declaration of Helsinki, the protocol was reviewed and approved by the institutional Ethics committee and all patients provided written informed consent.


We found statistically significant difference in the distribution of genetic mutation variants -1985G>T and P1170A C>G among the patients with lung adenocarcinoma compared to healthy subjects (p < 0.001). The -1985G>T and P1170A C>G allelic variants were not significantly expressed among the patient and control groups in overall subject (p = 0.874).


Our study indicates that the expressions of genetic variants -1985G>T and P1170A C>G is associated with higher risk of development of lung adenocarcinoma. There was no statistical difference among patient and control groups in overall subjects.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.